InvestorsHub Logo
Post# of 316478
Next 10
Followers 364
Posts 113777
Boards Moderated 5
Alias Born 12/28/2000

Re: None

Tuesday, 08/14/2018 1:48:05 PM

Tuesday, August 14, 2018 1:48:05 PM

Post# of 316478
OPTN down 29% posted better-than-expected Q2 results earlier today.
The culprit may be management's commentary on revenue and average selling price (ASP) for XHANCE (fluticasone propionate) Nasal Spray, approved by the FDA almost a year ago for the treatment of nasal polyps.
https://seekingalpha.com/news/3382579-optinose-23-percent-q2-report

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.